Michael Ackermann
Director at Tarsus Pharmaceuticals, Inc. (TARS)
Michael Ackermann has filed 11 insider reports with the SEC since June 2021, as director at Tarsus Pharmaceuticals, Inc. (TARS). Michael Ackermann made no open-market purchases or sales in the last 12 months. The latest filing, on July 1, 2022, reports grant or award at Tarsus Pharmaceuticals, Inc. (TARS).
- Filings
- 11
- Companies
- 1
- Bought on market
- $1.35M
- Sold on market
- $657K
Companies where Michael Ackermann is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 1,208,273 | $1.35M | $657K | $13.50 | $73.01+441% | Jul 1, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Jun 16, 2022TARSSEC Form 4 filed by Ackermann MichaelForm 4Grant or award
- Jun 15, 2022TARSSEC Form 4: Ackermann Michael converted options into 4,257 shares, increasing direct ownership by 0.35% to 1,208,273 unitsForm 4Exercise or conversion of a derivative
- May 5, 2022+$1.35MTARSSEC Form 4: Ackermann Michael bought $1,350,000 worth of shares (100,000 units at $13.50)Form 4Open-market purchase
- Dec 1, 2021-$144KTARSSEC Form 4: Ackermann Michael sold $143,934 worth of shares (5,833 units at $24.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 1,204,016 unitsForm 4Open-market sale10b5-1 plan
- Nov 1, 2021-$162KTARSSEC Form 4: Ackermann Michael sold $162,289 worth of shares (5,833 units at $27.82) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 1,209,849 unitsForm 4Open-market sale10b5-1 plan
- Oct 12, 2021-$148KTARSSEC Form 4: Ackermann Michael sold $148,000 worth of shares (5,633 units at $26.27) as part of a pre-agreed trading plan, decreasing direct ownership by 0.46% to 1,215,682 unitsForm 4Open-market sale10b5-1 plan
- Oct 8, 2021-$5,006TARSSEC Form 4: Ackermann Michael sold $5,006 worth of shares (200 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.02% to 1,221,315 unitsForm 4Open-market sale10b5-1 plan
- Sep 1, 2021-$147KTARSSEC Form 4: Ackermann Michael sold $147,237 worth of Common Stock (5,833 units at $25.24), decreasing direct ownership by 0.48% to 1,221,515 unitsForm 4Open-market sale10b5-1 plan
- Aug 11, 2021-$15.6KTARSSEC Form 4: Ackermann Michael sold $15,619 worth of Common Stock (621 units at $25.15), decreasing direct ownership by 0.05% to 1,227,348 unitsForm 4Open-market sale10b5-1 plan
- Aug 5, 2021-$34.6KTARSSEC Form 4: Ackermann Michael sold $34,576 worth of Common Stock (1,383 units at $25.00), decreasing direct ownership by 0.11% to 1,231,798 unitsForm 4Open-market sale10b5-1 plan
- Jun 15, 2021TARSSEC Form 4: Ackermann Michael was granted 4,257 units of Common Stock, increasing direct ownership by 0.35% to 1,233,181 unitsForm 4Grant or award
Compare Michael Ackermann with
- Michael Ackermann vs Bobak R. Azamian1 shared
- Michael Ackermann vs Neera Clase1 shared
- Michael Ackermann vs Pyott David E I1 shared
- Michael Ackermann vs Link William J Phd1 shared
- Michael Ackermann vs Wendy L Yarno1 shared
- Michael Ackermann vs Seshadri Neervannan1 shared
Other insiders at the same companies
- Bobak R. AzamianTARS
- Neera ClaseTARS
- Pyott David E ITARS
- Link William J PhdTARS
- Wendy L YarnoTARS
- Elizabeth Yeu LinTARS
- Seshadri NeervannanTARS
- Aziz MottiwalaTARS
- Andrew D. GoldbergTARS
- Scott W MorrisonTARS
- Katherine GoodrichTARS
- Bhaskar ChaudhuriTARS
- Jeffrey S FarrowTARS
- Dianne C. WhitfieldTARS
- Bryan WahlTARS
Questions about Michael Ackermann
- What is Michael Ackermann's role at Tarsus Pharmaceuticals, Inc.?
- Michael Ackermann reports to the SEC as director at Tarsus Pharmaceuticals, Inc. (TARS), according to the latest filing on July 1, 2022.
- How many shares does Michael Ackermann own?
- After the latest filing that states it, Michael Ackermann directly owned 1,208,273 shares of Tarsus Pharmaceuticals, Inc. (TARS). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Michael Ackermann bought or sold stock recently?
- The most recent open-market purchase was on May 5, 2022: bought 100,000 shares of Tarsus Pharmaceuticals, Inc. (TARS) for $1.35M at an average of $13.50. The most recent open-market sale was on December 1, 2021: sold 5,833 shares of Tarsus Pharmaceuticals, Inc. (TARS) for $144K at an average of $24.68.
- How do I get alerts when Michael Ackermann files?
- Follow Michael Ackermann on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Michael Ackermann (SEC CIK 0001791249). Totals count each trade once, skipping amendments whose original is on file, from Jun 17, 2021 on. View on SEC EDGAR · Get this as JSON